Clarus Therapeutics Holdings, Inc., an Illinois-based pharmaceutical enterprise established in 2003, primarily concentrates on the creation and commercialization of oral testosterone replacement therapies across the United States. Its key offering, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed for managing hypogonadism in men. The company also maintains strategic licensing agreements: one with HavaH Therapeutics for androgenic treatments aimed at inflammatory breast disease and specific forms of breast cancer, and another with The Royal Institution for the Advancement of Learning/McGill University to advance proprietary technology for addressing CoQ10 deficiencies.